Harlow, United Kingdom – July 2017 – Following the fantastic response and success in 2016, Merial Animal Health, in association with the BVNA, is proud to launch its ParasitXpert CPD Course and Award for the second consecutive year.
The bitesize course is online and worth 3 hours of certificated CPD, allowing nurses to extend their knowledge in the ever changing world of parasites and the diseases they can transmit. The course is a series of webinars, and relevant articles followed by an MCQ assessment.
All candidates attaining a distinction in the course are invited to submit a 500 word piece with the title “Putting parasite learnings into practice”. These entries will be judged by a panel including a technical vet from Merial and the Education Development Co-ordinator from BVNA.
The winner of the Award will be presented with a plaque at the official awards ceremony of this years’ BVNA Congress held on Friday 6 October and will receive a three-day Congress pass. They will also receive a comprehensive parasitology textbook plus £200 of Love2Shop vouchers. In addition, two highly commended entries will be awarded with a parasitology textbook and £100 of Love2Shop vouchers.
Sign up to the course is on the BVNA website (www.bvna.co.uk) using enrolment key PARASITXPERT2017. After viewing the webinars and articles, participants should complete the MCQ assessment. All entries must be received by 17 September 2017.
On January 1st, 2017, Merial became part of the Boehringer Ingelheim group. As the second largest animal health business in the world, Boehringer Ingelheim is committed to making the industry even better at improving animal health. With more than 10,000 employees worldwide, Boehringer Ingelheim Animal Health has products available in more than 150 markets and a global presence in 99 countries. For more information about Boehringer Ingelheim Animal Health, click here.
About Boehringer Ingelheim
Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates presently with a total of some 50,000 employees worldwide. The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. In 2015, Boehringer Ingelheim achieved net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3 per cent of net sales. For more information, please visit www.boehringer-ingelheim.com